PureTech Health plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTCHF research report →
About the company
PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic acetylcholine receptors for managing schizophrenia and the psychosis seen in Alzheimer's disease.
- CEO
- Robert Lyne
- IPO
- 2015
- Employees
- 80
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $413.81M
- P/E
- -3.49
- P/S
- 83.61
- P/B
- 1.24
- EV/EBITDA
- -1.64
- Div Yield
- 0.00%
- Gross Margin
- -468.52%
- Op Margin
- -2113.80%
- Net Margin
- -2355.32%
- ROE
- -31.98%
- ROIC
- -19.72%
- Revenue
- $4.76M · 10.37%
- Net Income
- $-112,179,583 · -309.64%
- EPS
- $-0.47 · -335.00%
- Op Income
- $-100,717,207
- FCF YoY
- 35.24%
- 52W High
- $1.92
- 52W Low
- $1.55
- 50D MA
- $1.75
- 200D MA
- $1.70
- Beta
- 0.81
- Avg Volume
- 10.42K
Get TickerSpark's AI analysis on PTCHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PTCHF coverage
Recent articles, reports, and earnings notes.
No research on PTCHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTCHF report →Similar companies
Peers in the same neighborhood.